The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models
Open accessAbstract
Idiopathic pulmonary fibrosis (IPF) is an aggressive interstitial lung disease with a high mortality rate. Putative drug targets in IPF have failed to translate into effective therapies at the clinical level. We identify TRAF2- and NCK-interacting kinase (TNIK) as an anti-fibrotic target using a predictive artificial intelligence (AI) approach. Using AI-driven methodology, we generated INS018_055, a small-molecule TNIK inhibitor, which exhibits desirable drug-like properties and anti-fibrotic activity across different organs in vivo through oral, inhaled or topical administration. INS018_055 possesses anti-inflammatory effects in addition to its anti-fibrotic profile, validated in multiple in vivo studies. Its safety and tolerability as well as pharmacokinetics were validated in a randomized, double-blinded, placebo-controlled phase I clinical trial (NCT05154240) involving 78 healthy participants. A separate phase I trial in China, CTR20221542, also demonstrated comparable safety and pharmacokinetic profiles. This work was completed in roughly 18 months from target discovery to preclinical candidate nomination and demonstrates the capabilities of our generative AI-driven drug-discovery pipeline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















![Extended Data Fig. 10 In vitro and in vivo study of INS018_055 on skin fibrosis. (a) IC50 values of inhibition effect of INS018_055 on levels of α-SMA expression, and levels of fibronectin and procollagen I in supernatant in cultured NHDF cells. Left: Cells were treated with INS018_055 and TGF-β (0.1 ng/ml) for 72 hours. The fluorescence intensity of α-SMA normalized to the total number of nuclei identified by staining with Hoechst 33258. Right and below: Cells were treated with INS018_055 and TGF-β (10 ng/ml) for 72 hours. Fibronectin and procollagen I contents were measured in the culture supernatants. Relative inhibition (%) = (Mean Stimulated control - Value)/ (Mean Stimulated control –Mean Non-stimulated control) X 100. All experimental conditions were performed in n = 5. (mean ± SEM). (b) INS018_055 inhibited collagen level in bleomycin induced skin-thickening rat model. Sprague Dawley rats were injected with 0.1 mL 1 mg/mL bleomycin subcutaneously into two sites on the shaved regions, once daily for 4 weeks. Treatments were administered with vehicle, Rapamycin (1.5 mg/kg, intraperitoneal) or INS018_055 (0.05%, 0.15% or 0.45%, topical), 30 minutes before administration of bleomycin, everyday for four weeks. Hydroxyproline and collagen content was measured (mean ± SD), (n = 5). The concentrations of hydroxyproline and collagen were normalized to total protein content using the Bradford method. Statistical analysis was performed using one-way ANOVA, then Dunnett’s multiple comparison test was performed. For hydroxyproline, compared with vehicle control group (Group 2), p values of Group naive control, Group of rapamycin, Groups of INS018_055 [0.05%, 0.15% and 0.45%], are 0.0165, 0.0085, 0.0015, 0.0261, and 0.0033, respectively. For total collagen, p values of Group naive control, Group of rapamycin, Groups of INS018_055 [0.05%, 0.15% and 0.45%], are 0.0025, 0.0003, 0.0001, 0.0004, and 0.0012, respectively. p values < 0.05 were considered statistically significant. Source data](https://figures.cochat.ai/paper-figures/1a89d8da10664767ad66389ff19331cc/a-small-molecule-tnik-inhibitor-targets-fibrosis-in-preclinical-and-clinical-figure-16.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“rentosertib (formerly ISM001-055), a first-in-class AI-generated small-molecule inhibitor of TNIK, a first-in-class target in idiopathic pulmonary fibrosis (IPF) discovered using generative AI.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We reported the development and positive phase 0 and 1 trial results of rentosertib9 (NCT05154240 and CTR20221542 (accessed via http://www.chinadrugtrials.org.cn/)), the first report of a targeted TNIK inhibitor entering clinical testing, which found rentosertib to be safe and well tolerated by healthy individuals, exhibiting a favorable pharmacokinetic (PK) profile in both trials9.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“our group used generative AI-driven discovery tools22,23 to identify Traf2- and Nck-interacting kinase (TNIK) de novo as a critical regulator of idiopathic pulmonary fibrosis (IPF) pathology as it orchestrates multiple profibrotic and proinflammatory cellular programs9.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our generative AI-powered approach streamlined preclinical candidate nomination to a mere 18 months and completion of phase 0/1 clinical testing to under 30 months from the initiation of target discovery, representing a revolutionary shift in the streamlining of drug discovery9.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An unintended consequence of rentosertib’s potential immunomodulatory mechanism of action9 may be a dampened site-specific immune response, potentially leading to increased susceptibility to infection, a known trigger for a subset of AE-IPF45,46.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [9]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 1×
“The WNT–β-catenin signaling pathway is involved in wound healing, regulates fibrogenesis and is known to contribute to EMT elicited by TGF-β stimulation 63 .”
An automated method for finding molecular complexes in large protein interaction networks
Bader, G. D., & Hogue, C. W. (2003) · BMC Bioinformatics · doi:10.1186/1471-2105-4-2 · Cited by 6,072 · cited 1×
“We used this single-cell dataset to simulate TNIK knockout in IPF myofibro-blasts using the scTenifoldKnk approach 54 followed by the Molecular Complex Detection (MCODE) algorithm 55 and performed pathway and biological process enrichment analysis.”
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V, & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,866
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Non-Transgenic Mouse Models of Kidney Disease
Rabe, M., & Schaefer, F. (2016) · Nephron · doi:10.1159/000445171 · Cited by 1,922
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868 · cited 1×
“As fibrosis can affect any organ and is responsible for up to 45% of all deaths in the industrialized world 51 , we hypothesized that inhibition of TNIK may provide therapeutic benefit in multiple pathologies in which fibrosis may be implicated.”
Chronic Kidney Disease Diagnosis and Management: A Review
Chen, T. K., Knicely, D. H., & Grams, M. E. (2019) · JAMA · doi:10.1001/jama.2019.14745 · Cited by 1,811
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765 · cited 2×
“In untreated patients, IPF has a highly inconsistent clinical course, with a median survival of 2 to 3 years 26 .”
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573 · cited 1×
“40,41,75–77) to discover the lead inhibitory compounds targeting this kinase.”
Self-citation
Research works printed but not linked: 1
- Aliper, A. et al. Prediction of clinical trials outcomes based on target choice and clinical trial design with multi-modal artificial intelligence. Clin. Pharmacol. Ther. 114, 972–980 (2023). · DOI
Cited by
Artificial intelligence in drug development
Zhang, K., Yang, X., Wang, Y., Yu, Y., Huang, N., Li, G., Li, X., Wu, J. C., & Yang, S. (2025) · Nature Medicine · doi:10.1038/s41591-024-03434-4 · Cited by 498
“…(https://pharma.ai/pandaomics/) successfully utilized multi-omics data and biological network analysis to recognize TRAF2-and NCK-interacting kinase as a potential target for anti-fibrotic therapy, leading to the development of a specific TRAF2-and NCK-interacting kinase inhibitor (INS018_055) 37 .”
Empowering biomedical discovery with AI agents
Gao, S., Fang, A., Huang, Y., Giunchiglia, V., Noori, A., Schwarz, J. R., Ektefaie, Y., Kondic, J., & Zitnik, M. (2024) · Cell · doi:10.1016/j.cell.2024.09.022 · Cited by 315
Ocana, A., Pandiella, A., Privat, C., Bravo, I., Luengo-Oroz, M., Amir, E., & Gyorffy, B. (2025) · Biomarker Research · doi:10.1186/s40364-025-00758-2 · Cited by 187
Machine learning-aided generative molecular design
Du, Y., Jamasb, A. R., Guo, J., Fu, T., Harris, C., Wang, Y., Duan, C., Liò, P., Schwaller, P., & Blundell, T. L. (2024) · Nature Machine Intelligence · doi:10.1038/s42256-024-00843-5 · Cited by 169
Xu, Z., Ren, F., Wang, P., Cao, J., Tan, C., Ma, D., Zhao, L., Dai, J., Ding, Y., Fang, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03743-2 · Cited by 180
“…and CTR20221542 (accessed via http://www.chinadrug-trials.org.cn/)), the first report of a targeted TNIK inhibitor entering clinical testing, which found rentosertib to be safe and well tolerated by healthy individuals, exhibiting a favorable pharmacokinetic (PK) profile in both trials 9 .”
InfluentialSelf-citation
Metadata
- Authors
- Ren, F., Aliper, A., Chen, J., Zhao, H., Rao, S., Kuppe, C., Ozerov, I. V., Zhang, M., Witte, K., Kruse, C., Aladinskiy, V., Ivanenkov, Y., Polykovskiy, D., Fu, Y., Babin, E., Qiao, J., Liang, X., Mou, Z., Wang, H., Pun, F. W., Torres-Ayuso, P., Veviorskiy, A., Song, D., Liu, S., Zhang, B., Naumov, V., Ding, X., Kukharenko, A., Izumchenko, E., & Zhavoronkov, A.
- Affiliations
- Hong Kong Science and Technology Parks Corporation (HK)
- Hangzhou Normal University (CN)
- Insilico Medicine (United States) (US)
- Universitätsklinikum Aachen (DE)
- Shanghai Medical College of Fudan University (CN)
- University of Chicago (US)
- Corresponding author
- Zhavoronkov, Alex
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2024-03-08
- Volume
- 43
- Issue
- 1
- Pages
- 63-75
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC11738990
- OpenAlex
- W4392596618
- Cited by
- 348
- References
- 90
- Citations by year
- 2026: 159 · 2025: 136 · 2024: 53
- FWCI
- 101.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Biotechnology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- TUScholarShare (Temple University) (submittedVersion, cc-by)
- RWTH Publications (RWTH Aachen) (submittedVersion, other-oa)
- Funders
- Nvidia
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- TNIK, idiopathic pulmonary fibrosis, fibrosis, small-molecule kinase inhibitors, artificial intelligence in drug discovery, generative AI, anti-inflammatory activity, pharmacokinetics, drug safety and tolerability, interstitial lung disease
- MeSH terms
- Animals, Artificial Intelligence, Double-Blind Method, Drug Evaluation, Preclinical, Female, Humans, Male, Middle Aged, Protein Serine-Threonine Kinases, Protein Kinase Inhibitors, Mice, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. https://app.cochat.ai/papers/10.1038/s41587-024-02143-0
- The paper
- Ren, F., Aliper, A., Chen, J., Zhao, H., Rao, S., Kuppe, C., Ozerov, I. V., Zhang, M., Witte, K., Kruse, C., Aladinskiy, V., Ivanenkov, Y., Polykovskiy, D., Fu, Y., Babin, E., Qiao, J., Liang, X., Mou, Z., Wang, H., . . . Zhavoronkov, A. (2025). A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology. https://doi.org/10.1038/s41587-024-02143-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.